دورية أكاديمية
Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study.
| العنوان: | Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study. |
|---|---|
| المؤلفون: | Duvignaud A; Inserm 1219, University of Bordeaux, and French National Research Institute for Sustainable Development, Bordeaux, France; Department of Infectious Diseases and Tropical Medicine, Division of Tropical Medicine and Clinical International Health, University Hospital Centre of Bordeaux, Hôpital Pellegrin, Bordeaux, France; Programme PAC-CI/ANRS Research Site, University Hospital Centre of Treichville, Abidjan, Côte d'Ivoire. Electronic address: alexandre.duvignaud@chu-bordeaux.fr., Jaspard M; Inserm 1219, University of Bordeaux, and French National Research Institute for Sustainable Development, Bordeaux, France; Programme PAC-CI/ANRS Research Site, University Hospital Centre of Treichville, Abidjan, Côte d'Ivoire; The Alliance for International Medical Action, Dakar, Senegal., Etafo IC; Lassa Fever Response Team, Infection Control and Research Centre, Federal Medical Centre Owo, Owo, Nigeria., Gabillard D; Inserm 1219, University of Bordeaux, and French National Research Institute for Sustainable Development, Bordeaux, France; Programme PAC-CI/ANRS Research Site, University Hospital Centre of Treichville, Abidjan, Côte d'Ivoire., Serra B; Inserm 1219, University of Bordeaux, and French National Research Institute for Sustainable Development, Bordeaux, France; Programme PAC-CI/ANRS Research Site, University Hospital Centre of Treichville, Abidjan, Côte d'Ivoire; The Alliance for International Medical Action, Dakar, Senegal., Abejegah C; Lassa Fever Response Team, Infection Control and Research Centre, Federal Medical Centre Owo, Owo, Nigeria., le Gal C; Inserm 1219, University of Bordeaux, and French National Research Institute for Sustainable Development, Bordeaux, France; Programme PAC-CI/ANRS Research Site, University Hospital Centre of Treichville, Abidjan, Côte d'Ivoire; The Alliance for International Medical Action, Dakar, Senegal., Abidoye AT; Lassa Fever Response Team, Infection Control and Research Centre, Federal Medical Centre Owo, Owo, Nigeria., Doutchi M; The Alliance for International Medical Action, Dakar, Senegal; Department of Infectious Diseases, National Hospital Centre of Zinder, Zinder, Niger., Owhin S; Lassa Fever Response Team, Infection Control and Research Centre, Federal Medical Centre Owo, Owo, Nigeria., Séri B; Inserm 1219, University of Bordeaux, and French National Research Institute for Sustainable Development, Bordeaux, France; Programme PAC-CI/ANRS Research Site, University Hospital Centre of Treichville, Abidjan, Côte d'Ivoire., Vihundira JK; The Alliance for International Medical Action, Dakar, Senegal., Bérerd-Camara M; The Alliance for International Medical Action, Dakar, Senegal., Schaeffer J; The Alliance for International Medical Action, Dakar, Senegal., Danet N; The Alliance for International Medical Action, Dakar, Senegal., Augier A; The Alliance for International Medical Action, Dakar, Senegal., Ogbaini-Emovon E; Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria., Salam AP; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Ahmed LA; Department of Family Medicine, Federal Medical Centre Owo, Owo, Nigeria., Duraffour S; Department of Virology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany., Horby P; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Günther S; Department of Virology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany., Adedosu AN; Viral Hemorrhagic Fever Laboratory, Infection Control and Research Centre, Federal Medical Centre Owo, Owo, Nigeria., Ayodeji OO; Lassa Fever Response Team, Infection Control and Research Centre, Federal Medical Centre Owo, Owo, Nigeria., Anglaret X; Inserm 1219, University of Bordeaux, and French National Research Institute for Sustainable Development, Bordeaux, France; Programme PAC-CI/ANRS Research Site, University Hospital Centre of Treichville, Abidjan, Côte d'Ivoire., Malvy D; Inserm 1219, University of Bordeaux, and French National Research Institute for Sustainable Development, Bordeaux, France; Department of Infectious Diseases and Tropical Medicine, Division of Tropical Medicine and Clinical International Health, University Hospital Centre of Bordeaux, Hôpital Pellegrin, Bordeaux, France; Programme PAC-CI/ANRS Research Site, University Hospital Centre of Treichville, Abidjan, Côte d'Ivoire. |
| مؤلفون مشاركون: | LASCOPE study group |
| المصدر: | The Lancet. Global health [Lancet Glob Health] 2021 Apr; Vol. 9 (4), pp. e469-e478. |
| نوع المنشور: | Journal Article; Observational Study; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101613665 Publication Model: Print Cited Medium: Internet ISSN: 2214-109X (Electronic) Linking ISSN: 2214109X NLM ISO Abbreviation: Lancet Glob Health Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [England] : Elsevier Ltd. 2013- |
| مواضيع طبية MeSH: | Palliative Care*, Lassa Fever/*mortality , Lassa virus/*isolation & purification , Ribavirin/*administration & dosage, Administration, Intravenous ; Adolescent ; Adult ; Age Factors ; Child ; Child, Preschool ; DNA, Viral/isolation & purification ; Female ; Follow-Up Studies ; Hospital Mortality ; Hospitalization/statistics & numerical data ; Humans ; Infant ; Infant, Newborn ; Kaplan-Meier Estimate ; Lassa Fever/diagnosis ; Lassa Fever/therapy ; Lassa Fever/virology ; Lassa virus/genetics ; Male ; Middle Aged ; Nigeria/epidemiology ; Pregnancy ; Prognosis ; Prospective Studies ; Reverse Transcriptase Polymerase Chain Reaction/statistics & numerical data ; Risk Factors ; Severity of Illness Index ; Time Factors ; Treatment Outcome ; Young Adult |
| مستخلص: | Background: Lassa fever is a viral haemorrhagic fever endemic in parts of west Africa. New treatments are needed to decrease mortality, but pretrial reference data on the disease characteristics are scarce. We aimed to document baseline characteristics and outcomes for patients hospitalised with Lassa fever in Nigeria. Methods: We did a prospective cohort study (LASCOPE) at the Federal Medical Centre in Owo, Nigeria. All patients admitted with confirmed Lassa fever were invited to participate and asked to give informed consent. Patients of all ages, including newborn infants, were eligible for inclusion, as were pregnant women. All participants received standard supportive care and intravenous ribavirin according to Nigeria Centre for Disease Control guidelines and underwent systematic biological monitoring for 30 days. Patients' characteristics, care received, mortality, and associated factors were recorded using standard WHO forms. We used univariable and multivariable logistic regression models to investigate an association between baseline characteristics and mortality at day 30. Findings: Between April 5, 2018, and March 15, 2020, 534 patients with confirmed Lassa fever were admitted to hospital, of whom 510 (96%) gave consent and were included in the analysis. The cohort included 258 (51%) male patients, 252 (49%) female patients, 426 (84%) adults, and 84 (16%) children (younger than 18 years). The median time between first symptoms and hospital admission was 8 days (IQR 7-13). At baseline, 176 (38%) of 466 patients had a Lassa fever RT-PCR cycle threshold (Ct) lower than 30. From admission to end of follow-up, 120 (25%) of 484 reached a National Early Warning Score (second version; NEWS2) of 7 or higher, 67 (14%) of 495 reached a Kidney Disease-Improving Global Outcome (KDIGO) stage of 2 or higher, and 41 (8%) of 510 underwent dialysis. All patients received ribavirin for a median of 10 days (IQR 9-13). 62 (12%) patients died (57 [13%] adults and five [6%] children). The median time to death was 3 days (1-6). The baseline factors independently associated with mortality were the following: age 45 years or older (adjusted odds ratio 16·30, 95% CI 5·31-50·30), NEWS2 of 7 or higher (4·79, 1·75-13·10), KDIGO grade 2 or higher (7·52, 2·66-21·20), plasma alanine aminotransferase 3 or more times the upper limit of normal (4·96, 1·69-14·60), and Lassa fever RT-PCR Ct value lower than 30 (4·65, 1·50-14·50). Interpretation: Our findings comprehensively document clinical and biological characteristics of patients with Lassa fever and their relationship with mortality, providing prospective estimates that could be useful for designing future therapeutic trials. Such trials comparing new Lassa fever treatments to a standard of care should take no more than 15% as the reference mortality rate and consider adopting a combination of mortality and need for dialysis as the primary endpoint. Funding: Institut National de la Santé et de la Recherche Médicale, University of Oxford, EU, UK Department for International Development, Wellcome Trust, French Ministry of Foreign Affairs, Agence Nationale de Recherches sur le SIDA et les hépatites virales, French National Research Institute for Sustainable Development. (Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.) |
| References: | BMJ. 2014 Jan 24;348:f7450. (PMID: 24464277) BMJ. 1988 Sep 3;297(6648):584-7. (PMID: 3139220) J Infect. 2020 Jun;80(6):671-693. (PMID: 32027872) Lancet Infect Dis. 2018 Jun;18(6):684-695. (PMID: 29523497) PLoS Pathog. 2016 May 18;12(5):e1005656. (PMID: 27191716) J Med Virol. 1988 Oct;26(2):127-35. (PMID: 3183637) Emerg Infect Dis. 2019 Aug;25(8):. (PMID: 31310586) PLoS Med. 2016 Mar 01;13(3):e1001967. (PMID: 26930627) Nat Med. 2017 Oct;23(10):1146-1149. (PMID: 28869611) J Infect Dis. 1987 Mar;155(3):437-44. (PMID: 3805771) J Infect Dis. 2016 Mar 15;213(6):934-8. (PMID: 26531247) J Infect Dis. 1987 Mar;155(3):445-55. (PMID: 3805772) Emerg Infect Dis. 2020 Nov;26(11):2625-2637. (PMID: 33079033) Am J Pathol. 1982 Jun;107(3):349-56. (PMID: 7081389) Trans R Soc Trop Med Hyg. 2015 Aug;109(8):483-92. (PMID: 26085474) Virol J. 2011 May 06;8:205. (PMID: 21548931) Crit Care. 2013 Feb 04;17(1):204. (PMID: 23394211) Nephron Clin Pract. 2012;120(4):c179-84. (PMID: 22890468) J Infect Dis. 1987 Mar;155(3):456-64. (PMID: 3805773) Science. 2019 Jan 4;363(6422):74-77. (PMID: 30606844) Emerg Infect Dis. 2019 Jun;25(6):1066-1074. (PMID: 31107222) Int J Infect Dis. 2019 Oct;87:15-20. (PMID: 31357056) Travel Med Infect Dis. 2020 Jul - Aug;36:101557. (PMID: 31978611) N Engl J Med. 1986 Jan 2;314(1):20-6. (PMID: 3940312) Int J Infect Dis. 2019 Jun;83:88-94. (PMID: 30930184) |
| معلومات مُعتمدة: | United Kingdom WT_ Wellcome Trust |
| فهرسة مساهمة: | Investigator: JF Alabi; MA Adedokun; AO Akinpelu; OO Oyegunle; TD Sule; J Etafo; AO Dede; MN Onyechi; MU Ireneh; O Gbenga-Ayeni; KG Fadiminiyi; PI Ehigbor; E Ouattara; S Karcher; L N'guessan-Koffi; I Ahyi; E Amani; M Diabaté; B Siloué; C Levy-Marchal; K Issaley; JP de Bruyne Mushenvula |
| المشرفين على المادة: | 0 (DNA, Viral) 49717AWG6K (Ribavirin) |
| تواريخ الأحداث: | Date Created: 20210319 Date Completed: 20210330 Latest Revision: 20210330 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC7970450 |
| DOI: | 10.1016/S2214-109X(20)30518-0 |
| PMID: | 33740408 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2214-109X |
|---|---|
| DOI: | 10.1016/S2214-109X(20)30518-0 |